Hyperactive self-inactivating piggyBac for transposase-enhanced pronuclear microinjection transgenesis by Marh, Joel et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Hyperactive self-inactivating piggyBac for transposase-enhanced pronuclear
microinjection transgenesis
Marh, Joel; Stoytcheva, Zoia; Urschitz, Johann; Sugawara, Atsushi; Yamashiro, Hideaki; Owens, Jesse
B; Stoytchev, Ilko; Pelczar, Pawel; Yanagimachi, Ryuzo; Moisyadi, Stefan
Abstract: We have developed a unique method for mouse transgenesis. The transposase-enhanced pronu-
clear microinjection (PNI) technique described herein uses the hyperactive piggyBac transposase to insert
a large transgene into the mouse genome. This procedure increased transgene integration efficiency by
fivefold compared with conventional PNI or intracytoplasmic sperm injection-mediated transgenesis. Our
data indicate that the transposase-enhanced PNI technique additionally requires fewer embryos to be mi-
croinjected than traditional methods to obtain transgenic animals. This transposase-mediated approach
is also very efficient for single-cell embryo cytoplasmic injections, offering an easy-to-implement transge-
nesis method to the scientific community.
DOI: https://doi.org/10.1073/pnas.1216473109
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-85225
Published Version
Originally published at:
Marh, Joel; Stoytcheva, Zoia; Urschitz, Johann; Sugawara, Atsushi; Yamashiro, Hideaki; Owens, Jesse
B; Stoytchev, Ilko; Pelczar, Pawel; Yanagimachi, Ryuzo; Moisyadi, Stefan (2012). Hyperactive self-
inactivating piggyBac for transposase-enhanced pronuclear microinjection transgenesis. Proceedings of
the National Academy of Sciences of the United States of America, 109(47):19184-19189.
DOI: https://doi.org/10.1073/pnas.1216473109
Hyperactive self-inactivating piggyBac for
transposase-enhanced pronuclear
microinjection transgenesis
Joel Marha, Zoia Stoytchevaa, Johann Urschitza, Atsushi Sugawaraa, Hideaki Yamashiroa,b, Jesse B. Owensa,
Ilko Stoytcheva, Pawel Pelczarc, Ryuzo Yanagimachia,1, and Stefan Moisyadia,d,1
aDepartment of Anatomy, Biochemistry, and Physiology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96822; bFaculty of Agriculture,
Niigata University, Niigata 950-2181, Japan; cInstitute of Laboratory Animal Science, University of Zurich, CH-8091 Zurich, Switzerland; and dManoa
BioSciences, Honolulu, HI 96819
Contributed by Ryuzo Yanagimachi, September 21, 2012 (sent for review August 1, 2012)
We have developed a unique method for mouse transgenesis. The
transposase-enhanced pronuclear microinjection (PNI) technique
described herein uses the hyperactive piggyBac transposase to in-
sert a large transgene into the mouse genome. This procedure in-
creased transgene integration efﬁciency by ﬁvefold compared with
conventional PNI or intracytoplasmic sperm injection-mediated
transgenesis. Our data indicate that the transposase-enhanced PNI
technique additionally requires fewer embryos to be microinjected
than traditional methods to obtain transgenic animals. This trans-
posase-mediated approach is also very efﬁcient for single-cell
embryo cytoplasmic injections, offering an easy-to-implement
transgenesis method to the scientiﬁc community.
transgene | genetically modiﬁed
Stable transgenesis by integration of exogenous DNA inmammalian zygotes can be achieved using several distinct
procedures that have been developed independently over the
past 30 y (1). The method most widely used to generate trans-
genic animals is pronuclear microinjection (PNI), whereby the
male pronucleus of a zygote is injected with linear transgene DNA.
PNI was originally developed in mice by Gordon et al. (2) and by
Brinster and colleagues (3) for rabbits, sheep, and pigs. In sub-
sequent studies, this method was also shown to allow for tissue-
speciﬁc expression by altering of the transgene’s promoter se-
quences, thus becoming the method of choice for generation of
transgenic animal models (3). PNI is a technique requiring con-
siderable embryo manipulation skill, and this passive transgenesis
technology relies on the endogenous repair mechanisms of the
zygote nucleus for transgene insertion, limiting its effectiveness
(4). Moreover, integration of the transgene occurs in a random
fashion, usually with multiple concatamerized copies in a single
locus after the ﬁrst cell division of the zygote (5–8). In mice, zygotes
transferred to surrogate mothers result in transgenic animals with
an efﬁciency rarely above 3.2% of embryos injected (ei), or 25%
of animals born (ab), with only 70% of the founders being germline
transgenic (8, 9). Additionally, a large number of these animals are
mosaic, and only about 50% express their transgene at adequate
levels (8). In livestock, such as pigs, cattle, and sheep, the high lipid
content of the oocyte or of one cell embryo makes it impossible
to visualize nuclear structures using a conventional light micro-
scope for implementing PNI (10).
Intracytoplasmic sperm injection-based transgenesis (ICSI-Tr)
relies on spermatozoa as DNA vectors (11). Here, spermatozoa
are membrane-damaged or demembranated by freeze-thawing
or treatment with Triton X-100, and they are then incubated with
linear transgene DNA. The exposed perinuclear theca of the
sperm head interacts with the transgene and serves as a carrier.
This sperm–DNA complex is then injected into the cytoplasm of
MII-arrested oocytes (oocytes injected, oi), and the transgene is
incorporated into the embryonic genome in a passive fashion via
the endogenous DNA repair mechanisms (4). As previously ob-
served for PNI, many transgenes integrate as multiple concat-
amerized vector copies (6, 8, 11, 12). ICSI-Tr, originally developed
to generate transgenic mice, has been extended with some success
to other species (13). However, the freeze-thawing procedure
causes chromosomal damage to some spermatozoa, resulting in
increased failure of embryos reaching term (14). As a consequence,
the original ICSI-Tr study reported that ∼100 oocytes were needed
to obtain 14 liveborn pups, of which 2 were transgenic (11). Such
modest levels of efﬁciency are acceptable for animals that are in-
expensive to house and can produce large numbers of offspring in
a single litter, but they are prohibitive for many farm animals, such
as cattle, that typically produce a single offspring per pregnancy. In
nonhuman primates, obtaining oocytes and achieving a successful
pregnancy can cost more than $10,000 in Europe; therefore, the
lower developmental efﬁciencies demonstrated by ICSI-Tr make
its implementation an expensive proposition (15).
The most efﬁcient method to date is viral transgenesis, initially
developed in rodents and then extended to farm animals (16, 17).
Here, disarmed lentiviral vectors are used to insert transgenes
actively at the single-cell embryo stage (16). Using this approach,
23% of the micromanipulated oocytes result in transgenic ani-
mals, with an overall percentage of 80% for ab. Among the dis-
advantages of this technique are the high embryo lethality (27%
survival percentage) and relatively small-sized cargo capacity of
9.5 kb due to the limited amount of DNA that can be packaged
within the viral particle (16). Furthermore, specialized contain-
ment facilities for lentiviral production are required, making it
prohibitive for many laboratories to use virus-based transgenesis.
Finally, the potential of recombinant events between the viral
vector and endogenous host viruses, leading to the generation
of new and more potent pathogenic agents, is of concern (1).
Therefore, the development of new transgenesis methods that
are safer and more efﬁcient and are not hampered by transgene
size limitations would be desirable.
We have recently developed an improved ICSI-Tr method that
uses the piggyBac transposase for efﬁcient gene transfer into the
mouse genome (18, 19). We have engineered unique piggyBac
plasmid vectors that contain the transposon cargo and the pig-
gyBac transposase gene on a single-helper independent plasmid
(pmGENIE-3). Moreover, the vector design facilitates self-in-
activation of the transposase on excision of the transposon.
These features were shown to reduce the construct’s genotoxic
potential while simultaneously improving transposon integra-
tion efﬁciency. We have demonstrated that this design allowed
us to reduce the number of transgene integrations markedly,
often to one per genome (19). Here, we report the development
of a series of unique hyperactive plasmid vectors (pmhyGENIE-
3) based on a previously described hyperactive mammalian
codon-optimized piggyBac transposase variant (20). We have
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evaluated the transgenesis efﬁciency of these constructs in
combination with standard transgenesis techniques, such as PNI
and ICSI. We have achieved transgene integration without
having to pretreat the spermatozoa during ICSI-Tr, thus facil-
itating embryo development percentages similar to traditional
nontransgenic ICSI methods (21). More importantly we have
used the pmhyGENIE system to develop a unique transgenesis
technique: transposase-enhanced pronuclear microinjection (te-
PNI). When using pmhyGENIE-3 plasmids in combination with
te-PNI, we achieved a far greater transgenic percentage than all
other methods currently used in mice. Furthermore, to develop a
transgenesis technique for application in livestock that facili-
tates improved development of microinjected zygotes to live
offspring, we explored direct cytoplasmic injections (CTIs) of the
pmhyGENIE-3 constructs into one-cell mouse embryos. This tech-
nique not only facilitated transgene integration, but the observed
transgenesis percentages using this method were signiﬁcantly higher
than for those for conventional PNI.
Results
Cell Culture Experiments with Improved pmGENIE Plasmids.We have
created unique self-inactivating hyperactive piggyBac transposase-
based plasmids (pmhyGENIE-3) for animal transgenesis. Build-
ing on our previously published pmGENIE constructs (19), we
have further improved these vectors to make them more effec-
tive for integrative gene transfer. As a ﬁrst step, we introduced
an SV40 enhancer sequence, which has been reported to increase
the transfer of plasmids from the cytoplasm into the nucleus (22–
24). Using pmGENIE-3-R6K in in vitro experiments, we noted a
40% increase in colony formation under identical transformation
and selection conditions compared with the original pmGENIE-
3 construct (Fig. 1). In a second modiﬁcation, we replaced the
mouse codon-biased piggyBac with the hyperactive piggyBac gene
(pmhyGENIE-3-R6K) (20). We observed improvements to the
transfection efﬁciency above those achieved with pmGENIE-3-
R6K. As a ﬁnal improvement, we engineered the vectors to feature
an antibiotic-free selection (pmhyGENIE-3-RNA-OUT) in bacteria
to conform to regulatory recommendations for the elimination of
antibiotic resistance markers during in vivo transfection and
transgenesis (25). A comparison of colony counts between the
original pmGENIE-3 plasmid and the newly developed hyper-
active plasmid constructs, as depicted in Fig. 1, demonstrates that
each of the improvements to the vectors either increases the
transfection efﬁciency (pmGENIE-3-R6K and pmhyGENIE-3-
R6K) or adds a signiﬁcant feature without reducing its efﬁciency
(pmhyGENIE-3-RNA-OUT) (Table S1).
Transgenesis via te-PNI. To establish a baseline for PNI efﬁciency
in our hands, we performed a set of PNI injections with a large-
bore pipette (2 μm) in combination with a Piezo actuator and with
a linear transgene matching the size of the pmhyGENIE-3 plas-
mid mammalian selection cassette (MSC) (Fig. 2 and Movie S1).
The movie demonstrates the low Piezo actuator pulses necessary
to penetrate the zona pellucida and the two membrane layers of
the embryo to reach the male pronucleus. Using this traditional
experimental setup for transgenesis, we achieved an efﬁciency of
2.0% for ei (Table 1), a result in the range of published PNI data
from several laboratories worldwide (9, 26). We next injected the
nonhyperactive pmGENIE-3-R6K-MSC into paternal pronuclei
by te-PNI (Table 2). Transgenic percentages for embryos micro-
manipulated ranged from 13.4–22.5% for ei and from 58.0–60.5%
for ab, a signiﬁcant increase over conventional PNI, which has
percentages of around 3.2% for ei and 24.0% for ab (9, 26).
In subsequent transgenesis experiments, we switched to the
hyperactive pmhyGENIE-3-RNA-OUT-MSC construct, because
this construct allowed us to perform transgenesis experiments
without antibiotic selection (Fig. 1 and Table 3).
As an initial step, we titrated plasmid concentrations ranging
from 0.25 to 40.0 ng/μL to obtain the optimal result for a given
plasmid concentration. The results, shown in Table 3, indicate
percentages comparable to PNI at lower concentrations, whereas
the highest concentration, 40.0 ng/μL, was lethal, and no live pups
were obtained presumably because the abundant amount of DNA
exerted toxic effects. The concentrations of 7.5 and 10.0 ng/μL
were most effective for transgenic animal production, and we
subsequently performed a large-scale microinjection series with
10.0-ng/μL injections. We obtained average percentages of 25.9%
for ei and 59.7% for ab (Table 3).
Traditional PNI with pmGENIE Plasmids. To compare te-PNI directly
with traditional PNI using our circular DNA constructs, we injec-
ted pmhyGENIE-3-RNA-OUT-MSC into the paternal pronuclei
of embryos via PNI, with narrow-bore pointed-tip pipettes and
no Piezo actuator. At 10-ng/μL plasmid concentrations, the
transgenic percentages for ei and ab were 2.1% and 100%,
respectively, showing that although the construct did perform
well in terms of generating transgenic mice, using it in the con-
text of classic PNI caused signiﬁcant embryo lethality. Decreasing
the DNA concentration to 2 ng/μL did improve embryo survival
percentages; however, transgene integration percentages dropped
to levels similar to those observed with PNI of standard linear
DNA (2.3% ei and 17.9% ab) (Table 3). All the transgenic founder
pups demonstrated variegated gene expression. These results
clearly demonstrate that the combination of pmGENIE plasmids
and improvements to PNI described above is necessary to obtain
increased transgenesis percentages.
Fig. 1. Comparison of plasmid transfection efﬁciencies in HEK293T cells. Each
of the improvements to the vectors either increases the transfection efﬁciency
or adds a signiﬁcant feature without reducing the efﬁciency (pB, piggyBac).
Fig. 2. Zona-drilling before te-PNI. The tip of the injection pipette is brought
into contact with the zona pellucida (1) of the one-cell embryo, and a Piezo
pulse is applied (2), allowing penetration of the pipette into the cytoplasm
(3). A second Piezo pulse is applied to allow pipette penetration through the
pronuclear membrane (4). The pronucleus is extended during plasmid injection
(5), and ∼130 copies of GENIE-3 plasmids are delivered into it. The pipette is
withdrawn (6). At no time during the te-PNI process is the embryo compressed.
(Magniﬁcation, 30×.)
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Transgenesis via CTI of pmhyGENIE-3-RNA-OUT-MSC Plasmid. To de-
velop a more efﬁcient transgenesis approach for livestock, in
which the high lipid content of the oocyte impedes visualization
of the nuclear structures by conventional light microscopic tech-
niques, we directly injected pmhyGENIE-3-RNA-OUT-MSC into
the cytoplasm of one-cell embryos of B6D2F2 zygotes. Again, we
titrated plasmid concentrations in 10-ng increments, starting at
the optimal concentration for te-PNI of 10.0 ng/μL and increasing
the DNA concentration up to 50.0 ng/μL (Table 4). We obtained
transgenic mouse pups at all plasmid concentrations with efﬁ-
ciencies comparable to or higher than previously published PNI
percentages (26). The best results were achieved at a plasmid
concentration of 10.0 ng/μL, resulting in average transgenic
percentages of 18.5% for ei and 34.5% for ab (Table 4).
ICSI-Tr.To avoid potential side effects caused by the pretreatment
of spermatozoa, we performed ICSI-Tr with pmhyGENIE-3-
RNA-OUT-MSC and fresh sperm. The percentages for oi were
low and sometimes did not result in transgenic pups at all. Using
spermatozoa treated with 10 mM NaOH as a control, we ob-
tained percentages similar to those previously reported (19)
(Table 5). With fresh sperm and the lowest plasmid concentra-
tion of 1.0 ng/μL, we observed percentages equivalent to those
obtained with NaOH treatment. Higher plasmid concentrations
resulted in a decrease in efﬁciency.
Monoclonal Antibody Studies to Assess piggyBac Localization Expressed
from pmhyGENIE Plasmids. Previously, we used a polyclonal antibody
to assess piggyBac localization expressed from newly developed
constructs synthesized with chimeric piggyBac transposases (19).
To gain an understanding of the functional competence of the
newly developed constructs synthesized with chimeric piggyBac
transposases, we performed immunolocalization with a newly
produced monoclonal antibody against the piggyBac protein.
The data obtained demonstrated expression patterns of nu-
clear localization for the de novo synthesized transposase protein
in mouse embryos, without nonspeciﬁc binding to endogenous
mouse proteins (Fig. 3). Immunolocalization persisted up to the
blastocyst stage.
Single-Copy Transgene Integration with pmhyGENIE-3-RNA-OUT-MSC.
Commonly used transgenesis techniques, such as PNI or ICSI-
Tr, often result in multicopy concatamerized transgene arrays
that frequently inﬂuence transgene expression (27). This con-
catamerized transgene phenomenon is believed to be due to the
ligation of linear transgenes in a head-to-tail orientation by the
homologous recombination mechanism of the oocyte DNA
repair machinery. The subsequent integration into the host ge-
nome is then mediated by nonhomologous recombination (5, 7,
28, 29). Gene transfer by the piggyBac transposase seems to avoid
such concatamers. During piggyBac transposition, a single trans-
poson is excised from the plasmid to form a synaptic complex.
The cut-and-paste mechanism of type II transposases appears to
ensure that only individual transgenes excised from the plasmid
participate in transposition (19). We used Southern blotting to
evaluate whether the methods described here show a propensity
for generating concatameric insertions. As shown in Fig. 4, all
zero ﬁlial (F0) animals produced by fresh sperm ICSI-Tr, te-PNI,
or CTI carried single-copy insertions, as additionally veriﬁed by
genomic site of insertion analysis (Fig. S3). All microinjection
techniques resulted in one to four insertions per animal. As we
described previously, this transgene copy range does not appear to
cause any detrimental mutations to F0 animals (19). The data in
Table S2 additionally demonstrate that all 18 F0 animals tested
for te-PNI were germline transgenic, giving rise to fully transgenic
ﬁrst ﬁlial (F1) generations. Of the 12 CTI animals tested, 10 were
germline transgenic, whereas for ICSI-Tr–mediated transgenesis
with fresh sperm, all four F0 animals tested passed on their trans-
gene through the germline to the F1 generation.
Genomic Site of Insertion Analysis. We previously reported trans-
poson insertion site analysis for ICSI-Tr–generated transgenic
animals, which was done with Vectorette PCR and inverse PCR
(19). For the current experiments, a nonrestrictive linear ampli-
ﬁcation-mediated (nrLAM) PCR approach was used for the
identiﬁcation of transpositionally generated sites of insertion
for te-PNI– and CTI-generated transgenic F0 animals. Two
insertion sites for te-PNI animals 2 and 3 and an additional two
insertion sites for CTI animals 1 and 2, depicted in Fig. 4, were
recovered (Fig. S3). Therefore, for each transgenesis approach
used, the genomic insertion of the transgene found in the
transposon is transpositionally generated.
Discussion
Transgenic animals were originally developed in rodent research
to model human diseases, such as cancer, heart disease, and
neurodegenerative disorders (e.g., Huntington disease, Alzheimer’s
disease) (30). The insights gained with these animals elucidated
gene functions at the molecular, cellular, and systems levels and
have helped unravel mechanisms in physiology and pathology.
Knowledge acquired in small rodents has been applied to large-
animal disease models and has paved the way for drug and bi-
ological therapy in medicine (31, 32). Recently, there has been an
interest in the transgenesis of ruminants because of their potential
Table 1. te-PNI done with a linear transgene containing a CAG-driven EGFP gene, SV40 promoter-driven hygromycin gene for selection
in mammalian cells, and a bacterially expressed kanamycin gene (7,244 bp)
No. of ei
(replicates)
Linear transgene
containing CAG-EGFP +
hygromycin + kanamycin
(7,244 bp), ng/μL
No. of embryos
survived
(% injected, ei)
No. of two-cell
stage embryos
transferred
(% injected, ei)
No. of surrogates
used for transfer
No. of liveborn
pups (% injected, ei)
[% transferred]
No. of EGFP-positive
pups (% injected, ei)
[% transferred]
{% born, ab}
110 (1) 2.0 106 (96.4) 106 (96.4) 7 27 (24.5) [25.5] 2 (1.8) [1.9] {7.4}
Table 2. te-PNI performed with pmGENIE-3-R6K-MSC
No. of ei
(replicates)
pmGENIE-3-
R6K-MSC, ng/μL
(ﬁnal fg concentration)
No. of
embryos survived
(% injected, ei)
No. of two-cell
stage embryos
transferred
(% injected, ei)
No. of surrogates
used for
transfer
No. of liveborn
pups (% injected, ei)
[% transferred]
No. of EGFP-positive
pups (% injected, ei)
[% transferred]
{% born, ab}
108 (3) H2O control 108 (100.0) 108 (100.0) 6 62 (57.4) [57.4] 0
134 (2) 3.5
(0.71)
123 (92.0) 70 (52.2) 6 31 (23.1) [42.3] 18 (13.4) [25.7] {58.0}
306 (6) 7.5
(1.53)
292 (95.4) 263 (85.9) 15 114 (37.3) [43.3] 69 (22.5) [26.2] {60.5}
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use as bioreactors for the production of valuable biomolecules (33).
However, the application of PNI to large animals is impeded by low
efﬁciency, concatamerized transgene insertion into the genome, and
unpredictable levels and patterns of transgene expression.
Only a few species are amenable to the micromanipulations
necessary for efﬁcient ICSI-Tr. For example, ICSI-Tr is inefﬁcient
in pigs, and therefore appears unsuitable for routine transgenic
production (34–36). Lentiviral-mediated transgenesis, on the other
hand, is very efﬁcient in delivering the transgene to the host
genome but results in multicopy insertions; as a consequence,
only a few micromanipulated embryos reach term, probably
due to lethal mutagenesis. Of the resulting live births however,
more than 80% are transgenic (16). High percentages of embryo
lethality are acceptable in mice but are more problematic in
species in which birth numbers are limited to one or two off-
spring per pregnancy.
We have therefore developed a unique transgenesis method
(te-PNI) that is at least ﬁvefold more efﬁcient in mice than
traditional PNI (for ei). te-PNI is based on using piggyBac
transposase vectors, larger diameter injection pipettes, and a
Piezo actuator. Transgenesis percentages with pmhyGENIE-3-
RNA-OUT-MSC at a concentration of 10 ng/μL (25.9% for ei
and 59.7% of ab, Table 3) demonstrate that in terms of efﬁciency,
te-PNI is equivalent to lentiviral transgenesis. Although varie-
gated expression of the transgene was fairly high for F0 animals at
∼70%, all transgenic offspring (F1) produced by these founders
Table 3. Summary of te-PNI performed with the pmhyGENIE-3-RNA-OUT-MSC plasmid
No. of ei
(replicates)
pmhyGENIE-3-RNA-
OUT-MSC, ng/μL
(ﬁnal fg concentration)
No. of embryos
survived
(% injected, ei)
No. of one-cell
or two-cell stage
embryos transferred
(% injected, ei)
No. of surrogates
used for
transfer
No. of liveborn
pups
(% injected, ei)
[% transferred]
No. of EGFP-positive
pups
(% injected, ei)
[% transferred]
{% born, ab}
15 (1) 0.25
(0.05)
13 (86.7) 13* (86.7) 1 6 (40.0) [46.2] 0 (0.0) [0.0] {0.0}
78 (1) 0.5
(0.10)
73 (93.6) 73* (93.6) 4 29 (37.2) [39.7] 2 (2.5) [2.7] {6.9}
70 (1) 1.0
(0.20)
60 (85.7) 60* (85.7) 3 20 (28.5) [33.3] 3 (4.3) [5.0] {15.0}
60 (1) 2.0
(0.40)
57 (95.0) 57* (95.0) 3 18 (30.0) [31.5] 3 (5.0) [5.3] {16.6)
65 (1) 4.0
(0.80)
62 (95.4) 62* (95.4) 3 8 (37.0) [12.9] 2 (3.1) [3.2] {25.0}
137 (3) 7.5
(1.53)
113 (82.5) 113* (82.5) 7 33 (24.1) [29.2] 15 (10.9) [13.3] {45.5}
88 (1) 10.0
(2.04)
78 (88.6) 78* (88.6) 6 20 (22.7) [25.6] 19 (21.6) [24.4] {95.0}
70 (2) 20.0
(4.08)
63 (90.0) 28† (40.0) 2 4 (5.7) [14.3] 0 (0.0) [0.0] {0.0}
60 (1) 40.0
(8.16)
53 (88.3) 19† (31.7) 2 0 (0.0) [0.0] 0 (0.0) [0.0] {0.0}
799 (14) 10.0
(2.04)
764 (95.6) 700† (87.6) 45 347 (43.4) [49.6] 207 (25.9) [29.6] {59.7}
562 (4) 2.0
(0.40)
362 (64.4) 362*,‡ (64.4) 17 74 (13.2) [20.4] 13 (2.3) [3.6] {17.6}
91 (1) 10.0
(2.04)
66 (72.5) 66*,‡ (72.5) 3 2 (2.1) [3.0] 2 (2.1) [3.0] {100}
*Embryos transferred at the one-cell stage.
†Embryos transferred at the two-cell stage.
‡Injections performed by traditional PNI with a 0.1- to 0.2-μm internal diameter pipette and the help of an automated microinjector.
Table 4. CTI performed with a 2-μm internal diameter pipette and a Piezo actuator
No. of ei
(replicates)
pmhyGENIE-
3-RNA-OUT-MSC, ng/μL
(ﬁnal fg concentration)
No. of embryos
survived
(% injected, ei)
No. of two-cell
stage embryos
transferred
(% injected, ei)
No. of surrogates
used for
transfer
No. of liveborn
pups
(% injected, ei )
[% transferred]
No. of EGFP-positive
pups
(% injected, ei)
[% transferred]
{% born, ab}
156 (5) 10.0
(2.04)
127 (81.4) 126 (80.8) 9 84 (53.8) [66.6] 29 (18.5) [23.0] {34.5}
83 (2) 25.0
(5.10)
77 (92.7) 65 (78.3) 5 33 (39.8) [50.8] 10 (12.0) [15.4] {30.3}
40 (1) 35.0
(7.14)
40 (100.0) 40 (100.0) 3 17 (35.0) [35.0] 1 (2.5) [2.5] {7.1}
30 (1) 40.0
(8.16)
30 (100.0) 30 (100.0) 2 13 (30.0) [30.0] 3 (10.0) [10.0] {10.0}
25 (1) 50.0
(10.20)
25 (100.0) 25 (100.0) 2 14 (20.0) [20.0] 3 (12.0) [12.0] {60.0}
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displayed transpositionally generated uniform and robust trans-
gene expression. All experiments were performed in mice; how-
ever, we believe that the techniques described herein can be
easily adapted for other species. Future research in livestock will
determine if the timing of transcription initiation from plasmid
DNA in large-animal zygotes differs from that in mice because that
may inﬂuence the effectiveness of this approach for these animals.
CTI of pmGENIE plasmids was approximately fourfold more
efﬁcient than traditional PNI. This approach might therefore
provide a valuable tool for transgenesis in species in which visu-
alization of the pronuclei is difﬁcult due to high lipid content in the
oocyte or zygote. Additionally, the injection of DNA into the cy-
toplasm of zygotes is considerably less cumbersome compared with
other transgenesis micromanipulation techniques, and can there-
fore be applied without the technical expertise necessary for PNI.
By using ICSI-Tr implemented with fresh sperm for the fer-
tilization of oocytes, we aimed to avoid potential detrimental
effects to the spermatozoa caused by the treatment necessary
to adhere DNA to their surface. The highest transgenesis per-
centages were attained using the lowest plasmid concentration
and were comparable to those obtained with NaOH-treated sperm.
Higher plasmid concentrations resulted in lower efﬁciencies, po-
tentially due to the possibility that these concentrations prove toxic
to the embryos. Another factor inﬂuencing ICSI-Tr efﬁciency is
that the injections of plasmids during fertilization are performed
at a very early developmental stage, whereas injections for te-
PNI and CTIs take place at the later developmental stage of two
pronuclei. This difference of 6 h may be critical for the persistence
of episomal plasmids that may be exposed to nucleases present in
the cytoplasm before the initiation of transcription at the two-cell
stage. Increasing the plasmid concentration increases the number
of vectors available at this developmental time point but appears
to have a negative effect on embryo survival.
Comparing the efﬁciency of different transgenesis techniques
reported by individual research groups can be challenging. For
example, the ratio of total animals born (tab)/animals transgenic
(at) has been used previously. Two prior publications on trans-
posase-based transgenesis stated tab/at ratios of 34.8% (37) and
37% (38), but the number of micromanipulated embryos (ei) was
omitted. Using this approach, we achieved efﬁciencies as high as
95% in one experiment, with an average of almost 60% for
10-ng/μL DNA plasmid injections (Table 3). However, because
transgenesis techniques suffer from poor postembryonic devel-
opment, this ratio does not necessarily reﬂect the overall efﬁ-
ciency of a particular technique. We believe that a more accurate
reﬂection of the effectiveness of a method is reporting transgenic
Table 5. Summary of ICSI-Tr injections performed with a 7-μm internal diameter pipette and a Piezo actuator
No. of oi
(replicates) Sperm treatment
pmhyGENIE-
3-RNA-OUT-MSC, ng/μL
(ﬁnal fg concentration)
No. of two-cell
stage embryos
transferred
(% injected, oi)
No. of
surrogates
used for
transfer
No. of liveborn
pups
(% injected, oi)
[% transferred]
No. of EGFP-positive
pups
(% injected, oi)
[% transferred]
{% born, ab}
75 (1) 10 mM NaOH 0.5
(0.10)
61 (81.3) 5 13 (17.3) [21.3] 4 (5.3) [6.6] {30.8}
99 (1) 10 mM NaOH 1.0
(0.20)
68 (68.7) 6 10 (10.1) [14.7] 4 (4.0) [5.9] {40.0}
57 (3) Fresh 1.0
(0.20)
52 (91.2) 3 16 (28.0) [30.8] 3 (5.3) [5.8] {18.8}
20 (1) Fresh 2.0
(0.40)
18 (90.0) 2 3 (15.0) [16.6] 0 (0.0) [0.0] {0.0}
140 (3) Fresh 5.0
(1.02)
92 (65.7) 10 17 (12.1) [18.5] 1 (0.7) [1.1] {5.9}
140 (2) Fresh 10.0
(2.04)
105 (75.0) 7 10 (7.1) [9.5] 1 (0.7) [1.0] {10.0}
220 (3) Fresh 15.0
(3.06)
84 (38.2) 7 0 (0.0) [0.0] 0 (0.0) [0.0] {0.0}
92 (4) Fresh 25.0
(5.10)
41 (44.6) 5 1 (1.1) [2.4] 0 (0.0) [0.0] {0.0}
113 (2) Fresh 50.0
(10.20)
54 (47.8) 5 3 (2.7) [5.6] 2 (1.8) [3.7] {66.6}
113 (2) Fresh 100.0
(20.40)
29 (25.7) 3 1 (0.9) [3.4] 0 (0.0) [0.0] {0.0}
200 (2) Fresh 200.0
(40.80)
9 (4.5) 2 1 (0.5) [11.1] 1 (0.5) [11.1] {100.0}
Fig. 3. Time course of piggyBac and EGFP protein expression in transgenic
embryos generated by te-PNI. Expression of piggyBac transposase (pBt) was
visualized by immunoﬂuorescence using a monoclonal antibody for the pBt
protein and is detectable above background levels at 36 h, corresponding to
the detection of EGFP transgene expression. DAPI was used to visualize nuclei.
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animals born as a ratio of total embryos micromanipulated; we
report here a transgenesis efﬁciency for te-PNI of 25.9%. This
percentage represents a signiﬁcant increase in efﬁciency, because
traditional PNI does not exceed 5% for ei/at. Unfortunately, a
direct comparison with the two previous reports mentioned above
is not possible. Additionally, other laboratories used transposase
mRNA for transgenesis (39–41). Although this approach is fea-
sible, we believe that te-PNI and CTI provide an improved ap-
proach because they do not require the manipulation of easily
degradable RNA molecules. In summary, the methods described
herein facilitate the production of transgenic animals with sig-
niﬁcantly increased transgenic percentages that are comparable
to lentiviral methods but simpler to implement.
Materials and Methods
Here, we provide a brief summary of the applied methods. A detailed de-
scription is provided in SI Materials and Methods.
Plasmid Development. The pmGENIE plasmids were constructed by basic mo-
lecular biology methods as described previously (19). The GATEWAY recom-
bineering method of Life Technologies was used for the construction of the
ﬁnal transposon-bearing pmhyGENIE plasmids by the use of LR Clonase en-
zyme (Life Technologies).
Cell Transfections. Cell culture and transfections were performed as described
previously (19).
Southern Blot Analysis. Southern blot analysis was performed as described
previously (19).
Transposon Insertion Sites. Genomic transpositional insertion sites were
identiﬁed by nrLAM-PCR, which has been described previously (42, 43).
Immunohistochemistry. After ﬁxation and removal of the zona pellucida,
oocytes were incubated with primary piggyBac antibody, followed by sec-
ondary antibody staining as described previously (19).
Transgenesis. The procedures were performed as previously described with
only minor modiﬁcations (12, 19, 44).
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